There are many companies working on TROP-2, mainly as antibody-drug conjugates and even if it's not very widespread in the context of prostate cancer, it is starting to gain traction.
Trop-2 is a promising therapeutic target in prostate cancer, particularly in aggressive subtypes like castration-resistant and neuroendocrine prostate cancer (NEPC), where it drives tumor growth, metastasis, and treatment resistance.
Its overexpression correlates with AR-V7, a marker of resistance to androgen therapies. Antibody-drug conjugates (ADCs), such as Sacituzumab govitecan, selectively deliver cytotoxic agents to Trop-2-positive cells, with efficacy tied to Trop-2 expression levels.
Preclinical studies link Trop-2 to neuroendocrine differentiation and suggest synergy with PARP inhibitors. Challenges include optimizing biomarkers for patient selection and managing ADC-related side effects.
Future research aims to refine combination therapies and validate Trop-2 as a predictive biomarker, offering new hope for advanced prostate cancer.
Cancer and Atherosclerosis targeting, A New Blood test to guide treatment, Targeting drug resistance in PCa
BCR May Not Be a Strong Surrogate End Point for Prostate Cancer Survival
